Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.63 |
| ▸ | DRD4 | P21917 | 5/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | UBE2M | P61081 | 1/20 | 0.60 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.60 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.59 |
| ▸ | CCR3 | P51677 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3731091 | 0.89 | DRD4 (0.68) | SIGMAR1DRD4DRD2SLC6A5CCR3 | |
| SCHEMBL20074561 | 0.87 | SIGMAR1 (0.60) | SIGMAR1DRD4DRD2UBE2MDCUN1D1 | |
| SCHEMBL7239441 | 0.84 | CCR3 (0.72) | SIGMAR1DRD4CCR3MEN1KMT2A | |
| SCHEMBL6580655 | 0.83 | HIF1A (0.56) | SIGMAR1DRD4DRD2UBE2MDCUN1D1 | |
| SCHEMBL7214415 | 0.82 | DRD4 (0.81) | SIGMAR1DRD4DRD2SLC6A5MEN1 | |
| SCHEMBL17729934 | 0.81 | CRHR1 (0.52) | MEN1KMT2A | |
| SCHEMBL62082 | 0.81 | SLC6A5 (0.81) | SIGMAR1DRD4DRD2SLC6A5MEN1 | |
| SCHEMBL14082643 | 0.80 | DRD4 (0.67) | SIGMAR1DRD4DRD2SLC6A5MEN1 | |
| Bicarbonate SCHEMBL7570498 | 0.79 | MTTP (0.48) | SIGMAR1DRD4DRD2UBE2MDCUN1D1 | |
| Bicarbonate SCHEMBL7568842 | 0.79 | CCR3 (0.48) | SIGMAR1DRD4SLC6A5CCR3SLC6A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10138206-B2 | Amorphous form of lomitapide mesylate | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2018-11-27 | — | — | US | disclosed |
| US-20170305858-A1 | AMORPHOUS FORM OF LOMITAPIDE MESYLATE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2017-10-26 | — | — | US | disclosed |
| WO-2016055934-A1 | AMORPHOUS FORM OF LOMITAPIDE MESYLATE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-04-14 | — | — | WO | disclosed |
| CN-101838218-A | Ester compound and pharmaceutical use of the same | JAPAN TOBACCO INC | 2010-09-22 | — | — | CN | disclosed |
| CN-1630629-B | Ester compound and medical use thereof | JAPAN TOBACCO INC | 2010-05-05 | — | — | CN | disclosed |
| CN-1943786-A | Ester compound and its medicinal application | JAPAN TOBACCO INC (JP) | 2007-04-11 | — | — | CN | disclosed |
| CN-1630629-A | Ester compound and medical use thereof | JAPAN TOBACCO INC (JP) | 2005-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138206-B2 | Amorphous form of lomitapide mesylate | LIPA, AUP1, LPXN | SIGMAR1 2594/4885DRD4 4606/4885DRD2 4578/4885 |
| US-20170305858-A1 | AMORPHOUS FORM OF LOMITAPIDE MESYLATE | LIPA, AUP1, LPXN | SIGMAR1 2594/4885DRD4 4606/4885DRD2 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.